Skip to content

ViaNautis Bio to present “polyNaut: non-viral, polymer-based targeted nanovesicles for systemic delivery to the central nervous system” at the ESGCT Annual Meeting

ViaNautis Bio to present “polyNaut: non-viral, polymer-based targeted nanovesicles for systemic delivery to the central nervous system” at the ESGCT Annual Meeting Targeted polyNaut® nanovesicles (tPNVs) are ViaNautis’ proprietary, polymer-based delivery platform, enabling cell‑specific targeting through nanobody conjugation. tPNVs offer…

ASGCT 2026: non-viral delivery under the spotlight

Post written by Adi Hoess, CEO Recently, Ray Jupp, CSO and I went to ASGCT’s 2026 annual meeting in Boston, which showcased a range of viral and non-viral delivery platforms. Excellent progress has been made with non-viral delivery and the…

ViaNautis Appoints Ray Jupp as Chief Scientific Officer

ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking biotechnology company at the forefront of genetic therapies, today announces the appointment of Dr Ray Jupp as Chief Scientific Officer (“CSO”), effective immediately. As CSO, Dr Jupp will be responsible for overseeing…

Back To Top